Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foreign Funds Enter Nationwide Hospital Operation And Management

This article was originally published in PharmAsia News

Executive Summary

Hong Kong-listed Golden Meditech has paid HK$830 million to purchase 70 percent of Daopei, China's largest blood disease specialist hospital. At the same time, the firm will gain business licenses and knowledge for national hospital operation and management through its 60 percent acquisition of Jianliang Hospital Management Co., which is the first foreign-owned enterprise qualified to run hospitals nationwide. The deal marks the entry of foreign funds into the sector. The acquisition will allow Golden Meditech to form a complete health care chain and optimize its business network in China's interior region. It will also bring synergy to its health care service, umbilical cord blood hematopoietic stem cell storage and application, as well as medical equipment production and sales. (Click here for more - Chinese Language)

You may also be interested in...



Genomma Enjoys Strong Q2 Thanks To Big Gains in US

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Executives On The Move: New CEOs At Alentis Therapeutics, Melinta Therapeutics And NBE-Therapeutics

New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.

Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India

After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel